Science & Enterprise subscription

Follow us on Twitter

  • Bio-engineers developed a process using the gene editing technique Crispr to design gel materials with properties a…
    about 7 hours ago
  • New post on Science and Enterprise: Crispr Deployed for Programmable Smart Hydrogels #Science #Business
    about 7 hours ago
  • New sponsored post on Science and Enterprise: Business Practices to Keep Retail Competitive with Online
    about 14 hours ago
  • An academic-industry collaboration is creating a non-invasive technique to detect rupture-prone plaque build-ups in…
    about 1 day ago
  • New post on Science and Enterprise: Math Model to Gauge Heart Attack Risk from Plaques #Science #Business
    about 1 day ago

Please share Science & Enterprise

Foundation, Pfizer Collaborate on Alzheimer’s Targets

Illustration of brain (NIDA)

(National Institute of Drug Abuse)

11 February 2015.  Alzheimer’s Drug Discovery Foundation and Pfizer’s Centers for Therapeutic Innovation are joining forces to sponsor research to find new Alzheimer’s disease drug targets. Financial details of the collaboration were not revealed.

The foundation and Pfizer plan to invest in project teams of Pfizer and academic scientists to translate academic research into candidates for small molecule drugs to treat Alzheimer’s disease and related dementias. The initial focus of the collaboration is expected to be new Alzheimer’s drug targets, with the deadline for pre-proposal submissions set for 13 February 2015.

Pfizer’s Centers for Therapeutic Innovation is a research and development network that partners with 25 academic medical centers and foundations to combine entrepreneurial approaches with collaborative science to bridge the gap between basic research and new treatments. The centers are located near academic research campuses in New York, Boston, San Francisco, and San Diego. Other foundation partners include Alliance for Lupus Research and Crohn’s and Colitis Foundation of America, with whom Pfizer shares decision-making on selecting projects for sponsorship and evaluating project progress.

Project teams will receive funding from both Alzheimer’s Drug Discovery Foundation and Pfizer, as well as access to Pfizer’s drug discovery resources, and the foundation’s expertise in Alzheimer’s disease research. Participation is open to current academic medical centers under Pfizer’s Centers for Therapeutic Innovation.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.